Each disease affects each patient in a particularly different manner, beyond the common diagnostic ground.
The OrganAID is a lab-based organoid technology designed to enhance the selection of the best treatment for every patient.,
The problem
There are not pharmacoresistant diseases, but there are suboptimal treatments. A diagnostic is the first step towards choosing a treatment, but each patient will react differently to the standardized treatment protocols.
Can we predict side effects before treatment? And, can we forecast the most effective treatment in a systematic manner? We definitely should go for it.
38%
Longer to approve CNS drugs compared to drugs for other indications
20%
Longer to develop CNS drugs
700 billion
Yearly economic burden of neurological diseases in USA
The solution
The OrganAID combines each patient’s sick tissue avatar, their own organoids, to have a reliable patient’s drug testing platform boosted by our propietary artificial intelligence multistep analysis.
Management Team
An interdisciplinary team with the collective objective
of improving life quality through personalized medicine
Sandra Acosta, PhD
Co-founder
Professor at University of Barcelona, with more than 15 years of experience modeling neural disorders in vitro. She is a recognised expert in neurodevelopmental and neurodegenerative disorders, genomics and organoid models.
Oscar Lao, PhD
Co-founder
Lead scientist at CSIC and professor at ESCI-UPF. Bioinformatian and human geneticist with more than 20 years of experience developing bioinformatic tools to understand human genetics.
Isabel Turpin
Co-founder
Biochemist specialized in brain organoids models for disease modeling, with an strong background in advanced microscopy. Academy for Women Entrepreneur prize recipient from Foment del Treball.
Contact Us
We value your feedback. Your words are important.